Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

UNCOVERED: An 8 billion reason why regeneron stock is in focus - The Untold Story

Regeneron Pharmaceuticals (REGN) stock is in focus after the company announced an expanded global alliance with long-term partner Sanofi (SNY). REGN said it will receive $1 billion in upfront cash and stands to earn up to $7 billion in milestone payments, driving the total potential value of the expanded contract to about $8 billion.

At the time of writing, Regeneron stock is down about 13% versus its recent high.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.